A method of treating blepharitis includes administering to the affected eye ofa subject an effective amount of anactive ingredient in an ophthalmically acceptable vehicle for a sufficientperiod of time to treat blepharitis. The active ingredientconsists essentially of a glucocorticoid in an ophthalmically acceptablevehicle that includes an aqueous polymer suspension thatwhen mixed with tear fluid provides a sustained release of said activeingredient. The aqueous polymer suspension includes acarboxyl-containing polymer having less than about 5% by weight cross-linkingagent and has a viscosity in a range from about1,000 to about 30,000 centipoises. A kit includes: (a) a compositioncomprising about 0.1% by weight dexamethasone in thisophthalmically acceptable vehicle and (b) instructions for using thecomposition of (a) for the treatment of blepharitis.
